Oxytocic Pharmaceuticals Market 2027 Snapshot | Industry Predict a Long-Term Growth at 10.5% CAGR by Revenue US$ 173.1 Million | Says, Coherent Market Insights
Labor induction is the procedure followed to stimulate uterine contractions during or before labor which lead to normal/vaginal birth. Synthetic oxytocins are widely used throughout labor and post-partum care in obstetrics. Oxytocic pharmaceuticals are manufactured synthetically and act similar to endogenous oxytocins by contracting uterine muscles. The drugs are administered through intravenous infusion/Injection or intramuscular injection.
The global oxytocic pharmaceuticals market is estimated to account for US$ 173.1 Mn in terms of value by the end of 2027.
Global Oxytocic Pharmaceuticals Market: Drivers
The increasing incidence of preterm births is expected to boost growth of the global oxytocic pharmaceuticals market during the forecast period. For instance, according to March of Dimes 2019 report card, the preterm birth rate in the U.S. reached 10.02% in 2018 from 9.63% in 2015.
Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3354
Global Oxytocic Pharmaceuticals Market: Opportunities
The increasing number of clinical trials to assess the efficacy of oxytocic drugs is expected to offer lucrative growth opportunities to players in the market. For instance, in October 2019, Wake Forest University Health Sciences started a randomized study to assess the effects of intramuscular oxytocin on pupil diameter and heart rate variability.
Global Oxytocic Pharmaceuticals Market: Restraints
Oxytocic drugs have some side effects such as redness or irritation at the injection site, loss of appetite, nausea, vomiting, cramping, and stomach pain, which are likely to hinder growth of the market.
The Intravenous Injection/Infusion segment in the global oxytocic pharmaceuticals market was valued at US$ 52.6 Mn in 2019 and is expected to reach US$ 117.2 Mn by 2027 at a CAGR of 10.5% during the forecast period. The increasing number of oxytocic pharmaceutical product approvals during the forecast period are expected to propel the growth of the segment.
The hospitals segment held dominant position in the global oxytocic pharmaceuticals market in 2019, accounting for 60.1% share in terms of value, followed by maternity clinics, respectively. Major factors attributing to the market dominance of the segment constitute of the increasing incidence of preterm births.
The postpartum haemorrhage segment held dominant position in the global oxytocic pharmaceuticals market in 2019, accounting for 76.5% share in terms of value, followed by labor arrest and inevitable abortion, respectively. The growth of the segment is attributed the increasing prevalence of postpartum haemorrhage during the forecast period
Physicians prefer IV bolus oxytocin during cesarean conditions. In Germany, bolus administration of oxytocin is used during cesarean conditions even though it creates more side effects when compared IV infusion doses. However, in the UK, slow infusion of 5-10 IU is mostly preferred.
The increasing hospitalization for labor procedures is expected to boost growth of the market. For instance, according to the National Health Commission, China’s rate of hospital delivery remained over 99% in recent six years, and the percentage in rural areas has seen a rise from 51.7% in 1996 to 99.8% in 2018.
Global Oxytocic Pharmaceuticals Market: Competitive Landscape
Major players operating in the global oxytocic pharmaceuticals market include, Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer Inc., Ferring B.V., Novartis AG, and Teva Pharmaceutical Industries Ltd.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3354
Global Oxytocic Pharmaceuticals Market: Competitive Landscape
September 2019: Fresenius Kabi SwissBioSim, a Fresenius Kabi company, started a new research and development center for biosimilars in Eysins, Switzerland.
October 2019: Granules India Limited announced to divest its entire equity shareholding in Granules Biocause Pharmaceuticals Co. Ltd. by selling its stake to joint venture partner Hubei Biocause Heilen Pharmaceutical Co. Ltd.
- Global Oxytocic Pharmaceuticals Market, By Indication:
- Abortion Induced Incomplete
- Inevitable Abortion
- Postpartum Haemorrhage
- Labor Induction
- Labor Arrest
- Global Oxytocic Pharmaceuticals Market, By Route of Administration:
- Intravenous Injection/Infusion
- Global Oxytocic Pharmaceuticals Market, By Source of Origin:
- Synthetic Oxytocin
- Natural Oxytocin (Animal Pituitary Extract)
- Global Oxytocic Pharmaceuticals Market, By End User:
- Maternity Clinics
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire